European Journal of Clinical Pharmacology

, Volume 66, Issue 2, pp 177–186 | Cite as

Outpatient utilization of drugs acting on nervous system: a study from the Republic of Srpska, Bosnia & Herzegovina

  • Vanda Marković-Peković
  • Svjetlana Stoisavljević-Šatara
  • Ranko Škrbić
Pharmacoepidemiology and Prescription

Abstract

Purpose

The aim of this study was to analyse the utilization patterns of drugs acting on the nervous system in the Republic of Srpska, Bosnia & Herzegovina between 2002 and 2008.

Methods

This was a retrospective study aimed at analysing outpatient utilization of drugs reimbursed by the Health Insurance Fund, with a focus on the utilization of drugs acting on the nervous system. Anatomical therapeutic chemical/defined daily dose methodology was used to monitor drug utilization, and the drug utilization 90% (DU90%) method was used to assess drug prescribing.

Results

The most highly used drug subgroups were psycholeptics and antiepileptics followed by the psychoanaleptics. Anxyolitics comprised the most prescribed pharmacological subgroup over the whole study period, but a decrease was observed in 2007 and 2008. Following updating of the list with selective serotonin re-uptake inhibitor drugs, particularly sertraline, antidepressant use increased fivefold in 2008 compared to 2006. Tramadol was the predominant opioid analgesics in terms of utilization, while the use of oral morphine was low. Diazepam was the most highly prescribed drug, followed by phenobarbital and carbamazepine. The list update with the new generation drugs was immediately reflected in the DU90% profile.

Conclusions

The observed tendency toward increased total drug utilization observed in our study is comparable to worldwide trends. Implementation of new clinical guidelines for nervous diseases and updating of the list of reimbursable drugs with the addition of new ones contributed to the observed improvement in prescribing patterns in primary healthcare during the study period. The DU90% is shown to be a simple rough method for assessing prescribing quality. More stratified analyses should be performed on a routine basis to ensure a rational use of medicines and a cost-efficient use of limited healthcare resources.

Keywords

ATC/DDD methodology Drug utilization Drug utilization 90% profile Drugs acting on nervous system 

References

  1. 1.
    Smith G (2003) Drug prescribers and pharmaceutical carers in integrated health care. Pharm J 271:380–383Google Scholar
  2. 2.
    World Health Organization (2004) Atlas: country resources for neurological disorders. WHO, GenevaGoogle Scholar
  3. 3.
    World Health Organization (2006) Neurology and public health—facts. Available at: http://www.who.int/mental_health/neurology/en/index.html Accessed 1 May 2009
  4. 4.
    World Health Organization (2001) Preventing suffering and death from mental disorders: European perspectives. The world health report. Press release EURO 11. WHO, Copenhagen Google Scholar
  5. 5.
    World Health Organization (2003) Investing in mental health. WHO, Geneva. Available at: http://www.who.int/mental_health/media/investing_mnh.pdf. Accessed 25 May 2009
  6. 6.
    Intercontinental Marketing Service (2004) Global pharmaceutical sales grew 7 percent to $550 billion. Available at: http://www.imshealth.com Accessed 1 May 2009
  7. 7.
    Intercontinental Marketing Service (2007) Top 10 global therapeutic classes. Available via http://www.imshealth.com. Accessed 13 May 2009
  8. 8.
    Marković Peković V (2008) Pharmacoepidemiological analyses of reimbursable medicines consumption over 2002-2006. PhD thesis. University of Banja Luka, Banja Luka Google Scholar
  9. 9.
    Marković Peković V, Škrbić R, Stoisavljević Šatara S (2009) Utilisation of cardiovascular medicines in Republic of Srpska, Bosnia & Herzegovina, five years study. Pharmacoepidemiol Drug Saf 18(6):320–326. doi:10.1002/pds.1704 CrossRefPubMedGoogle Scholar
  10. 10.
    Republika Srpska Institute of Statistics (2008) Republika Srpska in figures. Institute of Statistics, Banja Luka Google Scholar
  11. 11.
    Republika Srpska Institute of Statistics (2006) Demographic Statistical Bulletin No11. Institute of Statistics, Banja LukaGoogle Scholar
  12. 12.
    The Republic of Srpska Government (2006) Economic politics. Government of the Republic of Srpska, Banja LukaGoogle Scholar
  13. 13.
    The Republic of Srpska Government (2008) Economic politics. Government of the Republic of Srpska, Banja LukaGoogle Scholar
  14. 14.
    WHO Collaborating Centre for Drug Statistics Methodology (2005) ATC/DDD index. WHO Collaborating Centre, Oslo. Available at: http://www.whocc.no/atcddd/ Accessed 13 Jan 2009
  15. 15.
    Jakovljević V, Stanulović M, Sabo A, Mikov M (2000) ATC classification of medicines with DDDs for medicines on the market. OrtoMedics, Novi SadGoogle Scholar
  16. 16.
    Škrbić R, Marković Peković V, Stoisavljević Šatara S, Babić Đurić D (2001) ATC classification of medicines and monitoring of consumption of medicines with DDD methodology for medicines with marketing authorisation in Republika Srpska. School of Medicine, Banja LukaGoogle Scholar
  17. 17.
    Bergman U, Popa C, Thomson Y, Wettermark B, Einarson TR, Aberg H et al (1998) Drug utilization 90%—a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol 54(2):113–118CrossRefPubMedGoogle Scholar
  18. 18.
    Wettermark B, Pehrsson A, Jinnerot D, Berman U (2003) Drug utilization 90% profiles—a useful tool for quality prescribing in primary health care in Stockholm. Pharmacoepidemiol Drug Saf 12(6):499–510CrossRefPubMedGoogle Scholar
  19. 19.
    Agency for Medicinal Products and Medical Devices Republic of Croatia (2004) Medicines consumption. Available at: http://www.almp.hr/?ln=hr&w=publikacije&d=promet_lijekova_2004 Accessed 13 May 2009
  20. 20.
    Agency for Medicinal Products and Medical Devices Republic of Croatia (2005) Medicines consumption. Available at: http://www.almp.hr/?ln=hr&w=publikacije&d=promet_lijekova_2005 Accessed 13 May 2009
  21. 21.
    Agency for Medicinal Products and Medical Devices of the Republic of Croatia (2006) Medicines consumption. Available at: http://www.almp.hr/?ln=hr&w=publikacije&d=promet_lijekova_2006 Accessed 13 May 2009
  22. 22.
    Medicines and Medical Devices Agency of Serbia (2006) Consumption of medicines 2004/2005. Medicines and Medical Devices Agency, BelgradeGoogle Scholar
  23. 23.
    Medicines and Medical Devices Agency of Serbia (2007) Consumption of medicines 2007. Medicines and Medical Devices Agency, BelgradeGoogle Scholar
  24. 24.
    Montenegro Health Insurance Fund (2006) Outpatient consumption of medicines in 2005. Montenegro Health Insurance Fund, PodgoricaGoogle Scholar
  25. 25.
    Montenegro Health Insurance Fund (2008) Outpatient consumption of medicines in 2007. Montenegro Health Insurance Fund, PodgoricaGoogle Scholar
  26. 26.
    Nordic Medico Statistical Committee (2004) Medicines Consumption in the Nordic Countries 1999–2003. Available at: http://www.nom-nos.dk/Medicinebook/medicines. Accessed 15 May 2009
  27. 27.
    Norwegian Institute for Public Health (2009) Drug Consumption in Norway 2004–2008. Available at: http://www.legemiddelforbruk.no/english/ Accessed 14 June 2009
  28. 28.
    The Norwegian Association of Pharmaceutical Manufacturers (2006) Facts and Figures. Available at: http://www.legemiddelstatistikk.com/tf/2006/files/english/about_lmi.html. Accessed 15 May 2009
  29. 29.
    National Agency for Medicines Finland (2008) Drug consumption in years 2004–2007. Available at: http://www.nam.fi/medicines/drug_consumption Accessed 10 Apr 2007
  30. 30.
    National Agency for Medicines Finland (2008) Drug consumption in 2008. Available at: http://www.nam.fi/medicines/drug_consumption Accessed 10 Apr 2009
  31. 31.
    Ministero della Salute Osservatorio Nazionale sull’Impiego dei Medicinali (2007) L’uso dei Farmaci in Italia. Available at: http://www.agenziafarmaco.it/allegati/rapporto_osmed_2007.pdf. Accessed 15 May 2009
  32. 32.
    Australian Institute of Health and Welfare (2003) Statistics on drug use in Australia in 2002. Cat. no PHE 4. Available at: http://www.aihw.gov.au/publications/phe/sdua02-c05.pdf Accessed 1 Feb 2008
  33. 33.
    Australian Institute of Health and Welfare (2008) Australia’s health no. 11. Available at: http://www.aihw.gov.au/publications/aus/ah08/ah08.pdf. Accessed 14 May 2009
  34. 34.
    Danish Medicines Agency (2008) Medicinal products Statistics in Denmark 2003–2007. Available at: http://www.dkma.dk/db/filarkiv/6692/Kapitel2.pdf Accessed 10 Apr 2009
  35. 35.
    Vrhovac B, Aganović I, Anić B, Barbarić-Babić V, Bakran I, Barić I et al (2003) Pharmacotherapeutical Manual, 4th edn. Medicinska naklada, ZagrebGoogle Scholar
  36. 36.
    Del Rio MC, Alvarez FJ (1996) How benzodiazepines are prescribed in primary health care settings in Spain. Therapie 51:185–189PubMedGoogle Scholar
  37. 37.
    Van Hulten R, Isacson D, Bakker A et al (2003) Comparing patterns of long-term benzodiazepine use between Dutch and Swedish community. Pharmacoepidemiol Drug Saf 12:49–53. doi:10.1002/pds.784 CrossRefPubMedGoogle Scholar
  38. 38.
    Grigoryan L, Haaijer-Ruskamp FM, Burgerdorf JGM, Mechtler R, Deschepper R, Tambic-Andrasevic A et al (2006) Self-medication with antimicrobial drugs in Europe. Emerg Infect Dis 12:452–459PubMedGoogle Scholar
  39. 39.
    Divac N, Jašović M, Đukić LJ, Vujnović M, Babić D, Bajčetić M et al (2004) Benzodiazepines utilization and self medication as correlates of stress in the population of Serbia. Pharmacoepidemiol Drug Saf 13:315–322. doi:10.1002/pds.940 CrossRefPubMedGoogle Scholar
  40. 40.
    Divac N (2004) Pharmacoepidemiological analysis of psychopharmaca in primary health care. PhD thesis. University of Belgrade, Belgrade Google Scholar
  41. 41.
    Štimac D, Vukušić I, Čulig J, Šostar Z (2007) Comparision of outpatient utilization of psychopharmaceuticals between Croatia and Scandinavian countries (2001–2003). Med Glas 4:14–20Google Scholar
  42. 42.
    Ciuna A, Andretta M, Corbari L, Levi D, Mirandola M, Sorio A et al (2004) Are we going to increase the use of antidepressants up to that of benzodiazepines? Eur J Clin Pharmacol 60(9):629–634CrossRefPubMedGoogle Scholar
  43. 43.
    Fürst J, Kocmur M (2003) Use of psychiatric drugs in Slovenia comparision to Scandinavian countries. Pharmacoepidemiol Drug Saf 12:399–403. doi:10.1002/pds.826 CrossRefPubMedGoogle Scholar
  44. 44.
    Ministry of Health and Social Welfare of the Republic of Srpska (2004) Guidelines for nervous diseases: Distimia. Ministry of Health and Social Welfare of the Republic of Srpska, Banja LukaGoogle Scholar
  45. 45.
    Ministry of Health and Social Welfare of the Republic of Srpska (2004) Guidelines for nervous diseases: anxious disorders. Ministry of Health and Social Welfare of the Republic of Srpska, Banja LukaGoogle Scholar
  46. 46.
    Ministry of Health and Social Welfare of the Republic of Srpska (2004) Guidelines for nervous diseases: depression and bipolar disorder. Ministry of Health and Social Welfare of the Republic of Srpska, Banja LukaGoogle Scholar
  47. 47.
    Pérez J, Marín N, Vallano A, Castells X, Capellà D (2005) Consumption and cost of antipsychotic drugs. Actas Esp Psiquiatr 33(2):110–116PubMedGoogle Scholar
  48. 48.
    Grohol JM (2006) Schizophrenia Treatment. Available at: http://www.psychcentral.com/disorders/sx31t.htm. Accessed 25 May 2009
  49. 49.
    Leucht S, Corves C, Arbter RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31–41CrossRefPubMedGoogle Scholar
  50. 50.
    Hajak G, Műller WE, Wittchen HU, Pittrow D, Kirch W (2003) Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98(10):1371–1378CrossRefPubMedGoogle Scholar
  51. 51.
    Hoffmann F, Pfannkuche M, Glaeske G (2008) High use of zolpidem and zopiclone. Cross-sectional study using claims data. Nervenarzt 79(1):67–72CrossRefPubMedGoogle Scholar
  52. 52.
    Prpić I, Paučić-Kirinčić E, Vlahović-Palčevski V (2001) Utilization of antiepileptic drugs in clinical centre Rijeka. Pharmaca 39:147–169Google Scholar
  53. 53.
    Paučić-Kirinčić E, Prpić I, Sasso A, Gazdik M, Modrušan-Mozetić Z, Vlahović-Palčevski V (2002) Antiepileptic drugs for the treatment of epilepsy and epileptics syndrome in childhood. Paediatr Croat 46:187–191Google Scholar
  54. 54.
    Freely M (1999) Drug treatment of epilepsy. Br Med J 318:106–109Google Scholar
  55. 55.
    Hudec R, Brozeková L, Foltán V, Tisonová J, Kriska M (2009) 5 most consumed opioid analgesics in Slovakia in the year 2006-comparision to five other countries (Finland, Norway, Denmark, Spain, Australia). Bratisl Lek Listy 110(5):316–318PubMedGoogle Scholar
  56. 56.
    Garcia del Poso J, Carvajal A, Viloria JM, Velasco A, Garcia del Poso V (2008) Trends in the consumption of opioid analgesics in Spain. Higher increases as fentanyl replaces morphine. Eur J Clin Pharmacol 64(4):411–415. doi:10.1007/s00228-007-0419-9 CrossRefGoogle Scholar
  57. 57.
    Hamunen K, Paakkari P, Kalso E (2008) Trends in opioid consumption in the Nordic countries 2002–2006. Eur J Pain. doi:10.1016/j.ejpain.2008.11.006 Google Scholar
  58. 58.
    Hudec R, Tisonová J, Brozeková L, Foltán V (2004) Trends in consumption of opioid analgesic in Slovak Republic during 1998–2002. Eur J Clin Pharmacol 60(6):445–448CrossRefPubMedGoogle Scholar
  59. 59.
    De Conno F, Ripamonti C, Brunelli C (2005) Opioid purchases and expenditures in nine western European countries:“Are we killing of morphine?”. Palliat Med 19(3):179–184. doi:10.1191/0269216305pm1002oa CrossRefPubMedGoogle Scholar
  60. 60.
    Štimac D, Čulig J (2009) Outpatient utilization of psychopharmaceuticals in the city of Zagreb. Psychiatr Danub 21(1):56–64PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Vanda Marković-Peković
    • 1
  • Svjetlana Stoisavljević-Šatara
    • 2
  • Ranko Škrbić
    • 2
  1. 1.Health Insurance FundBanja LukaBosnia and Herzegovina
  2. 2.School of Medicine, University of Banja LukaBanja LukaBosnia and Herzegovina

Personalised recommendations